Kindred Biosciences - KIN Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KIN, but not buy additional shares or sell existing shares.
View KIN analyst ratings or view top-rated stocks.

Kindred Biosciences, Inc. (NASDAQ:KIN) released its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences (NASDAQ:KIN) has a market capitalization of $0.00 and generates $42.16 million in revenue each year. The biopharmaceutical company earns $-21,800,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The official website for the company is kindredbio.com. The biopharmaceutical company can be reached via phone at (650) 701-7901 or via email at ir@kindredbio.com.